WT1基因在急性白血病患者中的表达及其临床意义  

Expression of WT1 in acute leukemia patients and its clinical significance

作　　者：曾春梅[1] 冉学红[2] 赵莎莎[1] 张曦[1] 

机构地区：[1]山东潍坊医学院,山东潍坊261042 [2]潍坊市人民医院血液科,山东潍坊261041

出　　处：《现代医药卫生》2011年第7期974-976,共3页Journal of Modern Medicine & Health

摘　　要：目的:探讨WT1基因在急性白血病(AL)患者中的表达情况及其临床意义。方法:采用实时定量RT-PCR方法动态检测60例初治AL患者WT1基因的表达,评估AL患者的缓解率、复发率及完全缓解后微小残留病(MRD)检测。结果:初治AML各亚型中M3基因表达阳性率最高,为82.4%,其WT1基因中位表达水平最高,达1 579.6,显著高于其他亚型,差异有统计学意义(P<0.05);AL患者中,WT1基因表达阳性组CR率显著低于阴性组,阳性组缓解后半年内复发率显著高于阴性组,差异均有统计学意义(均P<0.05),初治组、复发组及未缓解组AL患者WT1基因中位表达水平明显高于完全缓解组和对照组,差异有统计学意义(P<0.05)。结论:WT1基因在AL患者骨髓细胞中表达水平可作为临床评估疾病的发生、发展、判断预后及检测MRD的指标。Objective：To study the expression of Wilms＇ tumor gene（WT1） in acute leukemia（AL） patients and its clinical significance.Methods：Real-time quantitative reverse transcription polymerase chain reaction（RQ-RT-PCR） method was established for detecting dynamically WT1 expression levels in 92 cases of de novo AL.Results：The positive rate of WT1 expression of de novo AML M3 sub-type was the highest（82.4%）;the median expression level of WT1 in M3 sub-type of AML was the highest（1579.6）.It was significantly higher than that in the other sub-types of AML（P0.05）;the CR rate of AL patients in WT1 expression positive group was significantly lower than that in the negative group（P0.05）;the 6-month relapse rate after remission in the positive group was significantly higher than that in the negative group（P0.05）;the median expressions of WT1 in AL patients in de novo group,recurrence group and non-relieved group was significantly higher than those in the CR group and the control group（P0.05）.Conclusion：Expression of WT1 in AL patients can be a marker to evaluate occurrence,development and prognosis of the disease and to test minimal residual disease（MRD）.

关 键 词：急性白血病 实时定量RT-PCR WT1基因 

分 类 号：R5[医药卫生—内科学]